Select Publications
Journal articles
2009, 'High HIV testing and low HIV prevalence among injecting drug users attending the Sydney Medically Supervised Injecting Centre', Australian and New Zealand Journal of Public Health, 33, pp. 280 - 283, http://dx.doi.org/10.1111/j.1753-6405.2009.00389.x
,2009, 'Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation', Blood, 114, pp. 630 - 637, http://dx.doi.org/10.1182/blood-2009-02-202507
,2009, 'Immunosuppression and other risk factors for lip cancer after kidney transplantation', Cancer epidemiology biomarkers and prevention, 18, pp. 561 - 569, http://dx.doi.org/10.1158/1055-9965.EPI-08-0919
,2009, 'Modelling and calibration of the hepatitis C epidemic in Australia', Statistical Methods in Medical Research, 18, pp. 253 - 270
,2009, 'Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia', Journal of Gastroenterology and Hepatology, 24, pp. 436 - 442, http://dx.doi.org/10.1111/j.1440-1746.2008.05577.x
,2009, 'Quantifying the dose-response of walking in reducing coronary heart disease risk: Meta-analysis', European Journal of Epidemiology, 24, pp. 181 - 192, http://dx.doi.org/10.1007/s10654-009-9328-9
,2009, 'Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial', Clinical Infectious Diseases, 49, pp. 1591 - 1601
,2009, 'The pattern of excess cancer in dialysis and transplantation', Nephrology Dialysis Transplantation, 24, pp. 3225 - 3231, http://dx.doi.org/10.1093/ndt/gfp331
,2009, 'Thrombocytopenia is strongly associated with simian AIDS in pigtail macaques', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 51, pp. 374 - 379
,2008, 'A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand', Hepatology, 48, pp. 1062 - 1069
,2008, 'Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries', Journal of Gastroenterology and Hepatology, 23, pp. 922 - 929, http://dx.doi.org/10.1111/j.1440-1746.2007.05065.x
,2007, 'Causes of death in hepatitis B and C: a methodological issue', Lancet, 370, pp. 1033, http://dx.doi.org/10.1016/S0140-6736(07)61473-1
,2007, 'High Incidence of hepatitis C virus reinfection within a cohort of injecting drug users', Journal of Viral Hepatitis, 14, pp. 413 - 418
,2007, 'Liver cancer and hepatitis B and C in New South Wales, 1990-2002: a linkage study', Australian and New Zealand Journal of Public Health, 31, pp. 475 - 482
,2007, 'Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users', Epidemiology and Infection, 135, pp. 144 - 150
,2007, 'Predictors of completion of a hepatitis Bvaccination schedule in attendees at a primary health care centre.', Sexual Health, 4, pp. 27 - 30
,2006, 'Mortality in patients with hepatitis B or hepatitis C - Authors' reply', Lancet, 368, pp. 1767, http://dx.doi.org/10.1016/S0140-6736(06)69729-8
,2006, 'Cancer incidence in people with hepatitis B or C infection: A large community-based linkage study', Journal of Hepatology, 45, pp. 197 - 203
,2006, 'Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study', Lancet, 368, pp. 938 - 945
,2006, 'Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: The ALLIANCE Study', Antiviral Therapy, 11, pp. 409 - 419
,2006, 'Is screening for sexually transmitted infections in men who have sex with men who receive non-occupational HIV post-exposure prophylaxis worthwhile?', Sexually Transmitted Infections, 82, pp. 21 - 23
,2006, 'Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis', Clinical Cancer Research, 12, pp. 89 - 96
,2006, 'Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy', HIV Medicine, 7, pp. 105 - 111
,2006, 'Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individuals', AIDS Research and Human Retroviruses, 22, pp. 338 - 341
,2005, 'Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy', Journal of Antimicrobial Chemotherapy, 56, pp. 380 - 387
,2005, 'Cancer incidence in people with hepatitis B or C infection: A population based cohort study', Journal of Hepatology, 42, pp. 88 - 88
,2005, 'Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy', Journal of Gastroenterology and Hepatology, 20, pp. 1082 - 1086
,2005, 'Sexual behaviour and human herpesvirus 8 infection in homosexual men in Australia.', Sexual Health, 2, pp. 13 - 18
,2005, 'The normalized inhibitory quotient of boosted protease inhibitors is predictive of viral load response in treatment-experienced HIV-1-infected individuals', AIDS, 19, pp. 1393 - 1399
,2005, 'The use of a triple nucleoside-nucleotide-regimen for occupational HIV post-exposure prophylaxis', HIV Medicine, 6, pp. 191 - 197
,2004, 'Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: A meta-analysis of six prospective, randomized, comparative studies', Clinical Therapeutics, 26, pp. 92 - 97
,2004, 'Clearance of hepatitis C virus after newly acquired infection ininjection drug users', Journal of Infectious Diseases, 190, pp. 1270 - 1274
,2004, 'Hepatitis C virus incidence among injecting drug users on opioid replacement therapy', Australian and New Zealand Journal of Public Health, 28, pp. 576 - 578
,2004, 'HIV and hepatitis C coinfection within the CAESAR study', HIV Medicine, 5, pp. 174 - 179
,2004, 'Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study', AIDS, 18, pp. 1029 - 1036, http://www.medscape.com/viewarticle/474870
,2003, 'Combined Analysis of Two-Year Follow-Up from Two Open-Label Randomized Trials Comparing Efficacy of Three Nucleoside Reverse Transcriptase Inhibitor Backbones for Previously Untreated HIV-1 Infection: OzCombo 1 and 2', HIV Research & Clinical Practice, 4, pp. 252 - 261, http://dx.doi.org/10.1310/hct.2003.4.4.004
,2003, '229 Hepatitis C virus reinfection within a cohort of injecting drug users', Hepatology, 38, pp. 266 - 266, http://dx.doi.org/10.1016/s0270-9139(03)80272-0
,2003, 'Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2', HIV Clinical Trials, 4, pp. 252 - 261
,2002, 'Insulin resistance and HIV-related lipoatrophy [1] (multiple letters)', Journal of the American Medical Association, 288, pp. 1716, http://dx.doi.org/10.1001/jama.288.14.1716
,2002, 'Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study', HIV Research & Clinical Practice, 3, pp. 177 - 185, http://dx.doi.org/10.1310/hct.2002.3.3.001
,2002, 'A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia', AIDS, 16, pp. 2195 - 2200
,2002, 'Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy', JAMA - Journal of the American Medical Association, 288, pp. 207 - 215
,2002, 'For the MITOX investigators: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial', Journal of the American Medical Association, 288, pp. 207 - 215
,2002, 'Insulin resistance and HIV-related lipoatrophy', Journal of the American Medical Association, 288, pp. 1716
,2002, 'Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 infection: The OzCombo 2 Study', HIV Clinical Trials, 3, pp. 177 - 185
,2001, 'Hepatitis A epidemiology in Australia: national seroprevalence and notifications', Medical Journal of Australia, 174, pp. 338 - 341
,2000, 'Notifications of vaccine preventable diseases in Australia. Quarterly report (January-March 2000).', Communicable diseases intelligence, 24, pp. 239 - 241
,2000, 'Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998.', Communicable diseases intelligence, 24, pp. 276 - 277
,2000, 'Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998.', Communicable diseases intelligence, Suppl
,2000, 'Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998', Communicable Diseases Intelligence Quarterly Report
,